Bank of America’s Aegerion Pharmaceuticals AEGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-26,434
| Closed | -$79K | – | 7643 |
|
|
2016
Q3 | $79K | Sell |
26,434
-15,088
| -36% | -$26.1K | ﹤0.01% | 5547 |
|
|
2016
Q2 | $61K | Sell |
41,522
-4,807
| -10% | -$11K | ﹤0.01% | 5753 |
|
|
2016
Q1 | $171K | Sell |
46,329
-17,096
| -27% | -$106K | ﹤0.01% | 5222 |
|
|
2015
Q4 | $641K | Sell |
63,425
-14,267
| -18% | -$172K | ﹤0.01% | 4668 |
|
|
2015
Q3 | $1.06M | Sell |
77,692
-40,423
| -34% | -$720K | ﹤0.01% | 4286 |
|
|
2015
Q2 | $2.24M | Sell |
118,115
-81,076
| -41% | -$1.75M | ﹤0.01% | 3361 |
|
|
2015
Q1 | $5.21M | Sell |
199,191
-344
| -0.2% | -$8.75K | ﹤0.01% | 2456 |
|
|
2014
Q4 | $4.18M | Sell |
199,535
-1,095,307
| -85% | -$27.6M | ﹤0.01% | 2718 |
|
|
2014
Q3 | $43.2M | Buy |
1,294,842
+587,694
| +83% | +$18.2M | 0.01% | 920 |
|
|
2014
Q2 | $22.7M | Buy |
707,148
+260,171
| +58% | +$9.69M | 0.01% | 1315 |
|
|
2014
Q1 | $20.6M | Buy |
446,977
+150,938
| +51% | +$8.85M | 0.01% | 1272 |
|
|
2013
Q4 | $21M | Buy |
296,039
+58,272
| +25% | +$4.46M | 0.01% | 1287 |
|
|
2013
Q3 | $20.4M | Buy |
237,767
+170,626
| +254% | +$14.5M | 0.01% | 1265 |
|
|
2013
Q2 | $4.25M | Buy |
+67,141
| New | +$3.56M | ﹤0.01% | 2436 |
|
Bank of America's AEGR Position: Q4 2016 in Review
Bank of America sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 26,434 shares — an estimated $79K sold.
Bank of America first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $43.2M in Q3 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.
- Bank of America reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
- Bank of America sold 26,434 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $79K.
- Bank of America first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
- Bank of America's Aegerion Pharmaceuticals position peaked at $43.2M in Q3 2014.
- 0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.
Based on Bank of America's 13F filing for Q4 2016, filed 14 Feb 2017.